The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
November 16th 2024
Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Early Life BMI Plays Role in Future Diabetes and CVD Risk, Regardless of Adult BMI
June 22nd 2021Using 24 years of follow-up data from more than 12k adolescents provides insight into the impact of childhood BMI z-scores on risk of adverse health outcomes, including development of diabetes and premature myocardial infarction, in adulthood.
Study Details "Widespread" Use of Endocrine-Disrupting Chemicals in North American Cosmetic Products
June 17th 2021A study assessing levels of flourine in cosmetic products available in the US and Canada suggests many of these products could contain levels of chemicals that, over time, could cause harm.
Randomized Trial Suggests There is "Nothing Special" About Effects of Intermittent Fasting
June 17th 2021A randomized trial comparing 3 dietary approaches, including 2 involving fasting, suggests the recently popularized approach does not provide any substantial benefits compared to a traditional diet.
Discussing Bariatric Surgery Linked to Increased Weight Loss Whether or Not Patients Undergo Surgery
June 15th 2021A retrospective analysis of data from more than 30k patients with severe obesity suggests having a discussion about bariatric surgery with a clinician resulted in greater weight loss, regardless of if they underwent a bariatric procedure, but fewer than 9% had these discussions.
'Metabolically Healthy' Obesity Still Puts Patients at Increased Risk of Adverse Health Outcomes
June 14th 2021Data from the UK Biobank cohort details the increased risk of adverse health outcomes, including the development of diabetes and heart failure, among patients considered to have metabolically healthy obesity.
Women with Polycystic Ovary Syndrome at Increased Risk of Cardiovascular Disease Events
June 10th 2021A comparison of women with PCOS to matched controls indicates women with PCOS were at a 26% greater risk of experiencing major adverse cardiovascular events than their counterparts without polycystic ovary syndrome.
Study Suggests 2 Servings of Fruit Per Day Cuts Odds of Developing Diabetes by 36%
June 6th 2021An analysis of food frequency questionnaire and biomarker data from more than 7000 adults indicates consumption of 2 or more servings of whole fruit per day was associated with 36% lower odds of developing diabetes in the next half-decade.
Semaglutide (Wegovy) Approved for Chronic Weight Management in Patients with Obesity or Overweight
June 4th 2021The FDA has announced the approval of semaglutide 2.4 mg (Wegovy) for chronic weight management in patients with obesity or overweight—the first drug to receive such an approval from the FDA in more than half a decade.
USPSTF Issues Recommendation on Interventions for Healthy Weight Gain During Pregnancy
May 25th 2021The USPSTF has issued the organization's first recommendation on interventions for promoting healthy weight gain during pregnancy and also provided an overview of the evidence base used for the recommendation statement.
Single-Arm Study Finds Very-Low Calorie Ketogenic Diet Could Improve Testosterone Levels in Men
May 24th 2021A single-arm study examining the effects of a very-low calorie ketogenic diet over a 1-month period indicates the dietary approach was associated with improvements in body weight and sex hormones among men with overweight or obesity.
Subcutaneous Semaglutide Suppresses Appetite, Reduces Excess Energy Intake in Patients with Obesity
May 13th 2021A new phase 1 trial presented at ECO 2021 demonstrates the impact of semaglutide on appetite and body weight in patients with obesity, indicating use of the GLP-1 RA reduced energy intake 35% and resulted in a nearly 10% reduction in body weight over 20 weeks.